Know Cancer

or
forgot password

Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease: Changes in Biomarkers of Oxidative Stress, Profiles of Plasma Amino Acids and Their Derivatives and Brain Function


Phase 4
30 Years
80 Years
Open (Enrolling)
Both
Parkinson Disease, Parkinsonian Disorders, Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Movement Disorders, Neurodegenerative Diseases

Thank you

Trial Information

Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease: Changes in Biomarkers of Oxidative Stress, Profiles of Plasma Amino Acids and Their Derivatives and Brain Function


Inclusion Criteria:



1. Subjects with Idiopathic Parkinson's Disease

2. Subjects who are willing and able to participate in the trial and has provided
written, informed consent.

Exclusion Criteria:

1. Subjects who are allergic to Whey protein (HMS 90®).

2. Subjects who are treated with chemotherapy .

3. Subjects with any history of neurodegenerative diseases, e.g., Alzheimer's disease.

4. Subjects with history of diabetes. 4.5. Subjects with abnormal liver function test

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care

Outcome Measure:

Biomarkers of oxidative stress, i.e., plasma glutathione (reduced and oxidized forms), urinary 8-hydroxydeoxyguanosine, and urinary total antioxidant status

Outcome Time Frame:

6 months

Safety Issue:

Yes

Principal Investigator

Roongroj Bhidayasiri, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Chulalongkorn University

Authority:

Thailand: Ethical Committee

Study ID:

53653

NCT ID:

NCT01662414

Start Date:

April 2011

Completion Date:

December 2012

Related Keywords:

  • Parkinson Disease
  • Parkinsonian Disorders
  • Basal Ganglia Diseases
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Movement Disorders
  • Neurodegenerative Diseases
  • Basal Ganglia Diseases
  • Brain Diseases
  • Central Nervous System Diseases
  • Ganglion Cysts
  • Movement Disorders
  • Nervous System Diseases
  • Parkinson Disease
  • Parkinsonian Disorders
  • Neurodegenerative Diseases

Name

Location